Singapore markets closed

CSPC Pharmaceutical Group Limited (CSPCY)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
3.4400+0.0050 (+0.15%)
At close: 03:59PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 10.20B
Enterprise value 8.49B
Trailing P/E 12.57
Forward P/E 11.72
PEG ratio (5-yr expected) 2.62
Price/sales (ttm)2.35
Price/book (mrq)2.23
Enterprise value/revenue 0.27
Enterprise value/EBITDA 1.00

Trading information

Stock price history

Beta (5Y monthly) 0.72
52-week change 3-15.81%
S&P500 52-week change 322.43%
52-week high 34.0800
52-week low 32.6300
50-day moving average 33.1199
200-day moving average 33.1348

Share statistics

Avg vol (3-month) 328.51k
Avg vol (10-day) 314.52k
Shares outstanding 52.97B
Implied shares outstanding 63.03B
Float 88.26B
% held by insiders 10.00%
% held by institutions 10.01%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 40.14
Forward annual dividend yield 44.17%
Trailing annual dividend rate 30.25
Trailing annual dividend yield 37.39%
5-year average dividend yield 4N/A
Payout ratio 446.41%
Dividend date 311 Jul 2024
Ex-dividend date 403 Jun 2024
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Currency in CNY.

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 18.67%
Operating margin (ttm)23.59%

Management effectiveness

Return on assets (ttm)9.96%
Return on equity (ttm)18.22%

Income statement

Revenue (ttm)31.45B
Revenue per share (ttm)10.60
Quarterly revenue growth (yoy)1.90%
Gross profit (ttm)N/A
EBITDA 7.93B
Net income avi to common (ttm)5.87B
Diluted EPS (ttm)0.2700
Quarterly earnings growth (yoy)-15.10%

Balance sheet

Total cash (mrq)13.76B
Total cash per share (mrq)1.16
Total debt (mrq)706.9M
Total debt/equity (mrq)2.02%
Current ratio (mrq)2.63
Book value per share (mrq)2.80

Cash flow statement

Operating cash flow (ttm)4.18B
Levered free cash flow (ttm)1.16B